source
- Agenus surges on study pivot; Apnimed lines up an IPOAgenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.BioPharma Dive · 17d ago↗ source
- Busy M&A activity sets tone as biopharma earnings season kicks offWith the first half of 2026 officially in the books and another earnings season about to begin, a key question hangs over the biopharma industry: Will the good times continue? The answer to that ma…Endpoints · 17d ago↗ source
- Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trialPlus, news about Insilico, Ipsen, Q32 Bio, GSK’s Jemperli, Drug Farm and Padcev. ❌ FDA rejects Tris Pharma’s narcolepsy drug: Its rejection letter said that “additional information will be necessar…